References
- Andersson L, Berlin T, Boman I, et al. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol 1980; 213, Suppl. 55
- Benson R C, Jr., Gill G MG. Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 1986; 9: 341–351
- Byar D P, Corle D K. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 165–170
- Crawford E D, Eisenberger M A, McLeod D G, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. Eng J Med 1989; 321: 419–424
- Denis L J, Carneiro de Moura J L, Bono A, et al. Goserelin acetate and flutamide versus bilateral orch-ictomy: A phase III EORTC trial (30853). Urology 1993; 42(2)119–130
- Eklov S, Nilsson S, Larson A, Bjork P, Hartley-Asp B. Evidence for a nonestrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate 1992; 20: 43–50
- Esposti P. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biospy. Scand J Urol Nephrol 1971; 5: 199–209
- Gunnarsson. PO3 Davidsspn T, Andersson SB, Backman C, Johansson SA. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol 1990; 38: 189–193
- Janknegt R A, Abbou C C, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77–83
- Janknegt R A, Boon T A, van de Beek C, Grob P. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer. Proceedings of the International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer. 1996
- Jorgensen T, Tveter K J, Jorgensen L H. members of the SPCG-2 group. Total androgen suppression: Experience from the Scandinavian Prostate Cancer Group Study No. 2. Eur Urol 1993; 24: 466–170
- Kuhn M W, Weissbach L, Hinke A, for the prostate cancer study group. Primary therapy of metastatic prostate carcinoma with the depot gonadotropin releasing hormone analogue goserelin versus estramustine phosphate. Urology 1994; 43(2 Suppl)61–67
- Lundgren R, Nordle Ö, Josefsson K, South Sweden Prostate Cancer Study Group. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer. J Urol 1995; 153: 1580–1586
- Pavone-Macaluso M, de Voogt H J, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostate cancer: Final analysis of a randomized phase III trial of the European organization for research on treatment of cancer urological group. J Urol 1986; 136: 624–631
- Smith P H, Suciu S, Robinson M RG, et al. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: Final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 1986; 136: 619–623
- Soloway M S, Hardeman S W, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195–202
- Tew K D, Stearns M E. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 1987; 15: 155–160
- de Voogt H J, Smith P H, Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostate cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986; 135: 303–307